Similar @entity436 profiles in @entity706 with central nervous system involvement - possible biomarkers for XXXX selection for central nervous system prophylaxis, a retrospective study.

@entity1 @entity706 @entity1570 @entity149 @entity262 @entity22750 @entity1892 @entity14638 @entity9350 @entity436
Central nervous system (CNS) relapse occurs in around 5% of @entity1892 ( @entity1892 ) cases. No biomarkers to identify high-risk @entity1 have been discovered. We evaluated the expression of lymphocyte-guiding chemokine receptors in systemic and CNS @entity706 . Immunohistochemical staining for @entity436 , @entity22750 , @entity9350 , @entity1570 , and @entity14638 was performed on 89 tissue samples, including cases of @entity149 ( @entity149 ), secondary @entity149 (sCNSL), and systemic @entity1892 . Also, 10 reactive lymph node samples were included. Immunoelectron microscopy was performed on two PCNSLs, one sCNSL, one systemic @entity1892 , and one reactive lymph node samples, and staining was performed for @entity436 , @entity22750 , @entity1570 , and @entity14638 . Chi-square test was used to determine correlations between clinical parameters, diagnostic groups, and @entity436 expression. Strong nuclear @entity436 positivity correlated with systemic @entity1892 , whereas strong cytoplasmic @entity22750 positivity correlated with CNS involvement (P  =  0.003 and P  =  0.039). Immunoelectron microscopy revealed a nuclear @entity436 staining in reactive lymph node, compared with cytoplasmic and membranous localization seen in CNS @entity706 . We found that @entity149 presented a @entity436 profile different from @entity262 . Our findings give new information on the CNS tropism of @entity1892 and, if confirmed, may contribute to more effective targeting of CNS prophylaxis among @entity1 with @entity1892 .
